Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial

David I. Quinn, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Amir Goldkorn, Carol M. Moinpour, Mark G. Garzotto, Philip C. Mack, Michael A. Carducci, J. Paul Monk, Przemyslaw W. Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Celestia S. Higano, Nicholas J. Vogelzang, Ian M. Thompson

Research output: Contribution to journalArticlepeer-review

130 Scopus citations

Fingerprint

Dive into the research topics of 'Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Agricultural and Biological Sciences

Pharmacology, Toxicology and Pharmaceutical Science